Published in Vaccine Weekly, November 2nd, 2005
According to recent research published in the journal Cancer Research, "All-trans retinoic acid (ATRA) induces clinical remission in patients with t(15;17) acute promyelocytic leukemia (APL) carrying leukemogenic promyelocytic leukemia-retinoic acid receptor alpha(PML-RAR alpha) fusion protein by overcoming PML-RAR alpha transcriptional repression and inducing myeloid differentiation."
"To identify more potent chemical differentiation inducers, a screening assay was developed utilizing an ATRA-insensitive NB4 cell line (N-B4-c) in which...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly